Jason V Baker

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Chronic HIV disease and activation of the coagulation system
    Jason V Baker
    University of Minnesota, Hennepin County Medical Center, 701 Park Avenue, Mail Code G5, Minneapolis, MN 55415, United States Electronic address
    Thromb Res 132:495-9. 2013
  2. pmc Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 63:367-71. 2013
  3. pmc Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center HCMC, Minneapolis, Minnesota, USA
    PLoS ONE 7:e46894. 2012
  4. pmc HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 60:128-34. 2012
  5. pmc Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 25:2133-42. 2011
  6. pmc Cardiovascular implications from untreated human immunodeficiency virus infection
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, University of Minnesota, 701 Park Ave, MC G5, Minneapolis, MN 55415, USA
    Eur Heart J 32:945-51. 2011
  7. doi request reprint Biomarkers and HIV-associated cardiovascular disease
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55415, USA
    Curr Opin HIV AIDS 5:511-6. 2010
  8. pmc Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 56:36-43. 2011
  9. pmc Untreated HIV infection and large and small artery elasticity
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 52:25-31. 2009
  10. pmc The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms
    Jason V Baker
    University of Minnesota, Hennepin County Medical Center, Minneapolis, Minnesota, USA
    Curr Opin HIV AIDS 4:176-82. 2009

Detail Information

Publications23

  1. ncbi request reprint Chronic HIV disease and activation of the coagulation system
    Jason V Baker
    University of Minnesota, Hennepin County Medical Center, 701 Park Avenue, Mail Code G5, Minneapolis, MN 55415, United States Electronic address
    Thromb Res 132:495-9. 2013
    ..The clinical consequences of HIV-related changes in coagulation biology, the degree to which they are unique to HIV disease, and whether they can be mitigated through adjunct treatments, remains a focus of current research. ..
  2. pmc Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 63:367-71. 2013
    ..001), and interleukin-6 (r = 0.20, P = 0.04) levels. Future research should focus on mechanisms driving residual functional TF activity and whether these alterations have clinical consequences for non-AIDS-defining complications...
  3. pmc Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center HCMC, Minneapolis, Minnesota, USA
    PLoS ONE 7:e46894. 2012
    ..Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed...
  4. pmc HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 60:128-34. 2012
    ..Understanding the effects of HIV replication on endothelial dysfunction and platelet activation may identify treatment targets to reduce cardiovascular disease risk...
  5. pmc Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 25:2133-42. 2011
    ..The effects of initiating versus deferring ART on high-density and low-density lipoprotein particle (HDL-P and LDL-P, respectively) concentrations and apolipoprotein (Apo) levels are not well described...
  6. pmc Cardiovascular implications from untreated human immunodeficiency virus infection
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, University of Minnesota, 701 Park Ave, MC G5, Minneapolis, MN 55415, USA
    Eur Heart J 32:945-51. 2011
    ..Ultimately, additional adjunctive treatment will be needed to mitigate premature CVD risk among contemporary HIV-infected patients with access to ART...
  7. doi request reprint Biomarkers and HIV-associated cardiovascular disease
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55415, USA
    Curr Opin HIV AIDS 5:511-6. 2010
    ..Our goal is to summarize recent literature on biomarkers of cardiovascular disease (CVD) in the setting of HIV infection with an emphasis on those associated with clinical events...
  8. pmc Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 56:36-43. 2011
    ..Changes in these biomarkers have been described after stopping ART, but not after starting ART in SMART...
  9. pmc Untreated HIV infection and large and small artery elasticity
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 52:25-31. 2009
    ..Untreated HIV infection may increase risk for cardiovascular disease, and arterial elasticity is a marker of cardiovascular risk and early disease...
  10. pmc The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms
    Jason V Baker
    University of Minnesota, Hennepin County Medical Center, Minneapolis, Minnesota, USA
    Curr Opin HIV AIDS 4:176-82. 2009
    ..e. at higher CD4 cell counts than currently recommended by guidelines)...
  11. pmc Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases
    Jason V Baker
    Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 48:541-6. 2008
    ..Low CD4+ increases risk for both AIDS- and non-AIDS-related morbidity and mortality. The magnitude of CD4+ recovery early after initial antiretroviral therapy (ART) is important in the ultimate duration of immune depletion...
  12. pmc CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 22:841-8. 2008
    ..Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients...
  13. pmc Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection
    Jacqueline Neuhaus
    University of Minnesota, Minneapolis, Minnesota 55414, USA
    J Infect Dis 201:1788-95. 2010
    ..Human immunodeficiency virus (HIV) replication and immune activation may increase inflammation and coagulation biomarkers. Limited data exist comparing such biomarkers in persons with and without HIV infection...
  14. pmc HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation
    Jason V Baker
    Hennepin County Medical Center, Minneapolis, MN
    J Am Heart Assoc 2:e000264. 2013
    ..We hypothesized that HIV replication increases coagulation potentially through alterations in extrinsic pathway factors...
  15. pmc Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
    David R Boulware
    University of Minnesota, Minneapolis, Minnesota, USA
    J Infect Dis 203:1637-46. 2011
    ..Substantial morbidity occurs during the first year of antiretroviral therapy (ART) in persons with advanced human immunodeficiency virus (HIV) disease despite HIV suppression. Biomarkers may identify high-risk groups...
  16. pmc Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study
    Sonja M Bjerk
    Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 8:e56249. 2013
    ..Studies of biomarker associations with bacterial pneumonia risk in treated HIV-infected patients do not currently exist...
  17. doi request reprint Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort
    Jason V Baker
    aDepartment of Medicine, University of Minnesota bDivision of Infectious Diseases, Hennepin County Medical Center cDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota dNational Institute of Allergy and Infectious Disease NIAID, NIH, Bethesda, Maryland eNational Jewish Medical and Research Center, Denver, Colorado fWashington University School of Medicine, St Louis, Missouri gMiriam Hospital, Providence, Rhode Island hDivision of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia iAtherosclerosis Research Unit, University of Southern California jLos Angeles Biomedical Research Institute at Harbor UCLA, Los Angeles, California, USA
    AIDS 28:831-40. 2014
    ..Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positive patients will inform prevention strategies...
  18. ncbi request reprint Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease
    Alvaro H Borges
    aCentre for Health and Infectious Diseases Research CHIP, Department of Infectious Diseases and Reumathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark bThrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada cDepartment of Biostatistics dDepartment of Medicine, University of Minnesota eHennepin County Medical Center, Minneapolis, Minnesota, USA fINSERM U955 Equipe 16 gVaccine Research Institute VRI, Université Paris Est Créteil, Faculté de Médecine hService d Immunologie Clinique, Hopital Henri Mondor, AP HP, Creteil, France iNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jResearch Department of Infection and Population Health, University College London, London, UK kDepartment of Medicine, University of California, San Francisco, California, USA
    AIDS 28:1791-6. 2014
    ....
  19. pmc Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy
    Christopher J Miller
    Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 9:e95061. 2014
    ..Accurate estimates of disease incidence and of risk factors for these conditions are important in planning preventative efforts...
  20. pmc Collagen deposition limits immune reconstitution in the gut
    Jacob Estes
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Infect Dis 198:456-64. 2008
    ....
  21. pmc Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, USA
    Clin Infect Dis 53:826-35. 2011
    ..Persons with human immunodeficiency virus (HIV) infection are at risk for premature cardiovascular disease (CVD). Predictors of atherosclerotic disease progression in contemporary patients have not been well described...
  22. ncbi request reprint Inguinal lymph node biopsy in patients infected with the human immunodeficiency virus is safe
    David E Skarda
    Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
    Surg Infect (Larchmt) 8:173-8. 2007
    ..Additionally, we monitored the rates of other complications, namely, hematoma, dorsal vein thrombosis, epididymitis, lymphocele, and suture extrusion...
  23. pmc A case for treating high hepatitis B DNA levels before starting HIV therapy
    Jason V Baker
    AIDS 20:2402-3. 2006